Our Technology
Pyxis technology combines proprietary identification, quantification and purification of up to 30 immune, stroma and cancer cell populations from tumor biopsies. This is coupled with deep gene expression profiling of the purified cell populations. The unique high-resolution cellular and transcriptomic data collected is analyzed using machine learning approaches, which infer the inter-cellular communication network formed between different cell subsets found within the tumor.
From inter-cellular communication networks to predictive diagnostics and target discovery
Individual patients’ inter-cellular communication network
Tumor
Viable tumor dissociation
Flow cytometric sorting of tumor and immune cells
RNA sequencing library
Responders
Biomark Identification
Non-Responders
New drug combinations and/or new targets
Why is it so complex to find predictive biomarkers?
The fate of immunotherapy response is directed by the immune system, the tumor, and its microenvironment.
Accurate prediction requires deep understanding of the communication network of these three components - while Pyxis is the only company to implement this approach in this field
Many different cell types that can interact via direct contact or secretion of cytokine/chemokines
